Is Accutane a subsidiary of Roche?

Accutane is not a separate corporate subsidiary. It is a prescription drug brand owned and controlled directly by Roche Holding AG. The drug was developed internally by Roche, approved by the FDA in 1982, and has never been owned by any other company. The brand name Accutane was withdrawn from the U.S. market in 2009 but the product continues under the Roaccutane name in international markets, all under Roche's ownership.

Is Accutane publicly traded?

Accutane is not publicly traded as a separate entity. Roche Holding AG, the parent company, is listed on the SIX Swiss Exchange under the ticker ROG. Investors in Roche shares hold an indirect economic interest in the Roaccutane revenue generated in international markets, though Roche does not disclose separate financial results for individual products of this scale.

When was Accutane founded?

Accutane received FDA approval on May 7, 1982. Clinical research leading to the approval began in the mid-1970s based on isotretinoin studies conducted at the National Institutes of Health. Roche conducted subsequent pivotal trials and submitted the New Drug Application. The compound had been synthesized since 1955 but had no recognized therapeutic application until the dermatology research of the 1970s.

Who founded Accutane?

No single individual founded Accutane. Roche's internal research teams developed the product based on scientific work by Dr. Gary Peck and colleagues at the National Institutes of Health, who published findings on isotretinoin's effect on sebaceous glands in 1979 in the New England Journal of Medicine. Roche acquired the license to conduct commercial development and brought the drug to FDA approval in 1982.

What is Accutane's market position?

In the United States, Accutane no longer exists as a brand. Generic isotretinoin products collectively serve approximately 3.5 million annual prescriptions. Internationally, Roaccutane holds a premium market position in dermatology for severe acne treatment in markets across Europe, Latin America, and parts of Asia. Isotretinoin as a compound remains the only approved treatment that can produce long-term or permanent remission of severe nodular acne.

Has Accutane had recalls or controversies?

Accutane was not subject to a product safety recall, but it has faced major controversies. The most significant involve its severe teratogenicity (causing birth defects if taken during pregnancy), the mass tort IBD litigation that spanned from roughly 2008 to 2019, and ongoing debate about psychiatric adverse events including depression and suicidal ideation. These controversies shaped both the iPLEDGE program and ultimately Roche's decision to exit the U.S. market.

Is Roaccutane the same as Accutane?

Yes. Roaccutane is Roche's brand name for isotretinoin sold outside the United States. The active ingredient, formulation, and dosing are identical. The difference is only the trade name used in different markets. In the United States, the Accutane trademark was retained by Roche but is no longer used commercially. All isotretinoin available in the U.S. is sold under generic or other brand names.

Healthcare & Pharmaceuticals

Who Owns Accutane?

Accutane was developed and originally marketed by Roche Holding AG, a publicly traded Swiss pharmaceutical company headquartered in Basel, Switzerland (SIX: ROG). Roche discontinued the Accutane brand name in the United States in 2009 due to generic competition and mounting litigation costs. The active ingredient isotretinoin remains widely prescribed for severe nodular acne through generic manufacturers, and Roche continues to sell the product internationally as Roaccutane.

Parent Company

Roche

Founded

1982

Status

Publicly Traded

Headquarters

Basel, Basel-City, Switzerland

GlobalOfficial Website

Who Owns Accutane?

Parent Company: Roche
Ownership Type: Wholly owned
Company Type: Publicly Traded
Stock Ticker: SIX: ROG

Brand	Parent Company	Ownership Type
Accutane	Roche	Wholly owned

History of Accutane

Founded: 1982
Founders: Roche (internal development)

Isotretinoin is a synthetic retinoid, a chemical relative of vitamin A. The compound was first synthesized in 1955, but its dermatological applications were not recognized until the 1970s. Dr. Gary Peck at the National Institutes of Health conducted early studies documenting that isotretinoin dramatically reduced sebaceous gland activity and oil production. Those findings reached Roche's research teams, who initiated clinical development aimed at severe, treatment-resistant nodular acne.

The FDA approved Accutane on May 7, 1982, as the first oral prescription treatment specifically indicated for severe recalcitrant nodular acne. Dermatologists had lacked any effective systemic option for cystic acne patients who had failed repeated courses of antibiotics. Accutane filled that gap with a typical four-to-six-month treatment course that produced lasting remission in a substantial proportion of patients.

Sales grew steadily through the 1980s. By the early 1990s, Accutane was Roche's leading dermatology product, and by peak in the late 1990s, annual U.S. revenues reached approximately $700 million. Roche distributed the drug exclusively in the United States for the first decade, but as dermatology markets in Europe and Asia matured, the company rolled out Roaccutane across additional markets.

In 1988, the FDA required Roche to implement the Pregnancy Prevention Program after post-market surveillance linked isotretinoin exposure during pregnancy to severe fetal abnormalities, including brain, heart, and facial malformations. The program required pregnancy tests and contraception commitments for female patients of childbearing potential. This was replaced in 2006 by the iPLEDGE program, which extended registration requirements to prescribers, pharmacies, and all patients regardless of sex. At launch, iPLEDGE was one of the most restrictive risk management systems ever imposed on a prescription medication in the United States.

Roche's U.S. patent on isotretinoin expired in 2002. Generic versions entered the market quickly, and by 2008 they held more than 97% of U.S. isotretinoin prescriptions by volume. Simultaneously, Roche faced thousands of lawsuits, predominantly in New Jersey and Florida, alleging that Accutane caused inflammatory bowel disease. Several jury verdicts reached eight figures before appellate courts began overturning them on the grounds of insufficient scientific causation evidence. By 2019, the New Jersey Supreme Court dismissed 514 remaining IBD cases, largely ending the U.S. mass tort litigation. By that point, Roche had already exited the American market.

In June 2009, Roche stopped shipping Accutane to U.S. distributors. The company described the withdrawal as a business decision based on competitive economics and litigation costs, not a safety determination. Generic isotretinoin products remained on the market without interruption. As of May 2025, FDA-approved generic versions include Absorica (Sun Pharmaceutical Industries), Amnesteem (Mylan), Claravis (Teva), and Zenatane (Cerovene).

In December 2021, the FDA modified iPLEDGE to remove a binary gender categorization from the system, requiring the program instead to categorize patients by pregnancy risk. The change was implemented after trans and nonbinary patients reported substantial barriers to access caused by the previous system.

About Roche

Roche operates through two main business divisions: Pharmaceuticals and Diagnostics, creating a unique integrated healthcare company that combines treatment and diagnostic capabilities. This dual focus enables Roche to deliver personalized healthcare solutions, matching patients with the most effective treatments based on diagnostic information and molecular characteristics.

The Pharmaceuticals division develops and manufactures prescription medicines across multiple therapeutic areas, with particular strength in oncology, immunology, neuroscience, infectious diseases, and rare diseases. Roche's pharmaceutical portfolio includes both established blockbuster products and innovative new treatments that address significant unmet medical needs. The division maintains a global research and development network with facilities across multiple continents, investing billions annually in pharmaceutical innovation, clinical trials, and regulatory approvals.

The Diagnostics division produces laboratory testing systems, molecular diagnostics, and point-of-care testing devices that support healthcare professionals in disease detection, monitoring, and treatment selection. Roche's diagnostic capabilities include automated laboratory systems, molecular testing platforms, and digital health solutions. The division's integrated approach with pharmaceuticals creates unique advantages in personalized medicine, enabling precise treatment selection based on diagnostic information.

Roche's business philosophy emphasizes innovation, patient-centricity, and sustainable value creation. The company maintains a strong focus on research and development, with approximately 20% of pharmaceutical revenues invested in R&D activities. This investment supports a robust pipeline of new treatments and diagnostic solutions, with 10 key molecules advancing into phase III development in 2025 alone.

Financial performance in 2025 demonstrated the strength of Roche's integrated business model. The company reported 7% sales growth at constant exchange rates to CHF 61.5 billion, with the Pharmaceuticals Division achieving 9% growth and the Diagnostics Division growing 2%. Core operating profit increased by 13%, reflecting operational efficiency and strong demand for both pharmaceutical and diagnostic solutions.

Key growth drivers in 2025 included Phesgo for breast cancer, Xolair for food allergies, Ocrevus for multiple sclerosis, Hemlibra for hemophilia A, and Vabysmo for severe eye diseases. These products demonstrate Roche's strength across multiple therapeutic areas and its ability to deliver innovative treatments that address significant patient needs.

Looking toward 2026, Roche expects Group sales growth in the mid single digit range and core earnings per share growth in the high single digit range at constant exchange rates. The company plans to further increase its dividend to CHF 9.80 per share, which would mark the 39th consecutive dividend increase if approved by shareholders. For 2026, Roche is shifting focus from consolidation to optimization, emphasizing internal pipeline development and R&D process improvements to enhance productivity and decision-making.

Roche's strategic priorities include investing in programs with potential to redefine care standards, particularly in oncology, neuroscience, and immunology. The company maintains a $10 billion annual budget for potential acquisitions and partnerships, prioritizing strategic fit and scientific differentiation over transaction size. This approach reflects Roche's commitment to long-term value creation and sustainable growth while maintaining operational discipline.

Founded: 1896
Headquarters: Basel, Switzerland
Company Type: Publicly Traded
Stock: SIX: ROG
Revenue: CHF 61.5 billion (FY2025)
Employees: Approximately 101,000

Visit Roche website

View full company profile for Roche

Where Is Accutane Made / Based?

Headquarters: Basel, Basel-City, Switzerland
Manufacturing / Operations: Switzerland, Germany, Italy

Accutane Recalls & Controversies

Birth Defect Risk and iPLEDGE Program: Isotretinoin is classified as FDA Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high probability of severe fetal abnormalities. Birth defects documented in exposed pregnancies include hydrocephalus, microcephaly, cardiac malformations, and craniofacial defects. The iPLEDGE program was created specifically to prevent fetal exposure. A 2021 update removed the binary gender categorization from the system after documented access barriers for transgender and nonbinary patients. The program remains active and applies to all U.S. isotretinoin prescriptions.

Inflammatory Bowel Disease Mass Tort Litigation (2008 to 2019): Roche faced thousands of lawsuits in New Jersey and Florida alleging that Accutane caused Crohn's disease and ulcerative colitis. Several jury verdicts returned eight-figure awards against Roche. On appeal, courts in both states overturned many verdicts, finding that plaintiffs had not established scientific causation. In June 2019, the New Jersey Supreme Court dismissed 514 remaining IBD cases. Roche's total litigation defense spending was material to the company's decision to exit the U.S. market in 2009, two years before the bulk of appellate reversals occurred.

Psychiatric Risk and FDA Warnings (2005): The FDA updated Accutane labeling in 2005 to strengthen warnings about psychiatric adverse events, including depression, suicidal ideation, and completed suicides. Causal evidence has been disputed in peer-reviewed literature, with some studies finding no association after controlling for the psychological burden of severe acne itself. The black-box warning remains in effect for all isotretinoin products.

Cathflo Activase Sterility Recall (2024): This recall affected Cathflo Activase, not Accutane or Roaccutane. It is documented under the Activase brand page and is not associated with Accutane isotretinoin products.

Generic Competition and U.S. Market Exit (2009): Following patent expiration in 2002, generics captured nearly all U.S. volume within six years. Roche's revenue from the branded product fell sharply. Combined with litigation costs, the economics of continuing Accutane in the United States were unfavorable. The company's decision to withdraw was not a safety-driven action and did not affect the availability of isotretinoin for patients.

Brands Owned by Roche

Activase - Activase (alteplase) is a prescription thrombolytic medication manufactured by G...
Avastin - Groundbreaking anti-VEGF biologic cancer therapy (bevacizumab) developed by Gene...
CellCept - Prescription immunosuppressant medication for preventing organ rejection in tran...
Herceptin - Groundbreaking HER2-targeted biologic cancer therapy (trastuzumab) developed by ...
Kadcyla - Roche's HER2-targeted antibody-drug conjugate (ado-trastuzumab emtansine, T-DM1)...
Perjeta - Roche's HER2-targeted biologic (pertuzumab) developed by Genentech, FDA approved...
Rituxan - Roche's anti-CD20 chimeric monoclonal antibody (rituximab) co-developed by Genen...
Tamiflu - Oseltamivir antiviral medication invented by Gilead Sciences and licensed to Roc...
Tarceva - Roche's first-generation EGFR tyrosine kinase inhibitor (erlotinib) co-developed...
Tirosint - IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) ...
Xeloda - Roche's oral fluoropyrimidine chemotherapy (capecitabine) developed by Genentech...

View all brands owned by Roche

Accutane Ownership: Pros & Cons

Advantages

+Roche's global pharmacovigilance infrastructure provides decades of documented safety data supporting the continued use of isotretinoin in international markets
+Brand recognition built over 27 years in the U.S. market supports premium positioning for Roaccutane in markets where the brand remains active
+Roche's regulatory expertise across more than 80 markets facilitates ongoing international licensing and distribution
+The iPLEDGE safety framework, developed under Roche's stewardship, has become the standard model for high-risk medication risk management programs globally

Considerations

-The U.S. brand discontinuation in 2009 permanently ceded the largest single national market for isotretinoin to generic manufacturers
-Ongoing litigation risk, even in international markets where the IBD controversy has lower legal precedent, represents a continued liability for Roche's ownership position
-Generic competition in most markets limits pricing power for Roaccutane relative to its historical premium
-The iPLEDGE program, while necessary, generates access complaints that create reputational pressure on all isotretinoin brands including Roaccutane

Frequently Asked Questions About Accutane

Sources & Further Reading

Where to Buy

Disclosure: We may earn commission from purchases

Accutane on Amazon

Competitors to Accutane

These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.

Brand	Parent Company	Country	Founded	Market Position	Primary Market	Gender Target
Propecia	Merck	USA	1997	Premium	Global	Mens

Learn More About Competitors

Propecia

Owned by Merck & Co.

Prescription medication for treating male pattern baldness by inhibiting hair loss, manufactured and marketed by Merck & Co.

dermatologyhair-lossmale-pattern-baldness

Competitive Analysis

Market Positioning: Accutane competes with 1 brands in the same categories, ranging from mass market to luxury positioning.

Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.

Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.

Roche Stock Information

Jobs at Roche

Latest News About Accutane

People Also Searched

Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Brandpharmaceutical

Activase

Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.

Brand in Healthcare & Pharmaceuticals

thrombolyticstroke-treatment

Brandcontact-lenses

Acuvue

Acuvue is the world's leading contact lens brand, owned by Johnson & Johnson Vision Care, a division of Johnson & Johnson. The brand covers daily, weekly, and monthly disposable soft contact lenses sold in more than 100 countries.

Brand in Healthcare & Pharmaceuticals

vision-carejohnson-and-johnson

Brandoncology

Adcetris

Prescription antibody-drug conjugate treatment for classical Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphomas, co-developed by Seagen and licensed to Takeda Pharmaceutical.